NICE now recommends Revolade for ITP

The U.K.'s NICE issued draft guidance recommending the use of idiopathic thrombocytopenic purpura (ITP) drug Revolade eltrombopag from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), reversing the agency's 2010 final guidance. The recommendation is contingent on GSK providing Revolade at an undisclosed discount under a patient access scheme, which was not included in the 2010 guidance. NICE now recommends Revolade to treat chronic ITP in splenectomized patients who are refractory to other treatments and as a second-line treatment of non-splenectomized patients for whom surgery is contraindicated -- its approved indications. Comments are due Jan. 22, 2013. ...